Assignee
NUVATION BIO INC
US·18 granted patents·23 pending applications·32 citations·filing 2018–2024
Top patents by PatentIndex Score
41 records- 0194US11834458B2Anti-cancer nuclear hormone receptor-targeting compoundsNUVATION BIO INC·Filed 2022·Granted Dec 5, 2023·2 cites·34 claims
- 0293US12006314B2Anti-cancer nuclear hormone receptor-targeting compoundsNUVATION BIO INC·Filed 2022·Granted Jun 11, 2024·2 cites·17 claims
- 0392US11584756B2Heterocyclic compounds as BET inhibitorsNUVATION BIO INC·Filed 2020·Granted Feb 21, 2023·3 cites·31 claims
- 0490US11952349B2Anti-cancer nuclear hormone receptor-targeting compoundsNUVATION BIO INC·Filed 2020·Granted Apr 9, 2024·2 cites·10 claims
- 0590US11826430B2Anti-cancer nuclear hormone receptor-targeting compoundsNUVATION BIO INC·Filed 2020·Granted Nov 28, 2023·2 cites·8 claims
- 0690US11292782B2Diarylhydantoin compounds and methods of use thereofNUVATION BIO INC·Filed 2019·Granted Apr 5, 2022·6 cites·39 claims
- 0790US11034669B2Pyrrole and pyrazole compounds and methods of use thereofNUVATION BIO INC·Filed 2019·Granted Jun 15, 2021·6 cites·16 claims
- 0883US10793561B21,8-naphthyridinone compounds and uses thereofNUVATION BIO INC·Filed 2018·Granted Oct 6, 2020·3 cites·76 claims
- 0981US10807994B2Heterocyclic compounds and uses thereofNUVATION BIO INC·Filed 2018·Granted Oct 20, 2020·3 cites·59 claims
- 1080US12208141B2Anti-cancer nuclear hormone receptor-targeting compoundsNUVATION BIO INC·Filed 2023·Granted Jan 28, 2025·0 cites·19 claims
- 1179US11028058B2Heterocyclic compounds as adenosine antagonistsNUVATION BIO INC·Filed 2018·Granted Jun 8, 2021·2 cites·52 claims
- 1278US2025276978A1Heterocyclic compounds as bet inhibitorsNUVATION BIO INC·Filed 2024·Application pending·0 cites
- 1376US11174252B2Heterocyclic compounds as kinase inhibitorsNUVATION BIO INC·Filed 2019·Granted Nov 16, 2021·1 cites·106 claims
- 1474US2024352027A1Anti-cancer nuclear hormone receptor-targeting compoundsNUVATION BIO INC·Filed 2023·Application pending·0 cites
- 1573US2023339964A1Heterocyclic compounds as bet inhibitorsNUVATION BIO INC·Filed 2023·Application pending·0 cites
- 1668US12398121B2Anti-cancer nuclear hormone receptor-targeting compoundsNUVATION BIO INC·Filed 2022·Granted Aug 26, 2025·0 cites·12 claims
- 1765US2022213122A1Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitorsNUVATION BIO INC·Filed 2021·Application pending·0 cites
- 1864US2023118115A1SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINES AS WEE1 INHIBITORSNUVATION BIO INC·Filed 2022·Application pending·0 cites
- 1963US2023109104A1Heterocyclic compounds and uses thereofNUVATION BIO INC·Filed 2022·Application pending·0 cites
- 2062US11192900B2Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitorsNUVATION BIO INC·Filed 2019·Granted Dec 7, 2021·0 cites·25 claims
- 2162US2022298142A1Heterocyclic compounds as adenosine antagonistsNUVATION BIO INC·Filed 2022·Application pending·0 cites
- 2262US2022169648A11,8-naphthyridinone compounds and uses thereofNUVATION BIO INC·Filed 2022·Application pending·0 cites
- 2360US11306071B2Heterocyclic compounds as adenosine antagonistsNUVATION BIO INC·Filed 2020·Granted Apr 19, 2022·0 cites·20 claims
- 2460US2023062022A1Heterocyclic compounds as kinase inhibitorsNUVATION BIO INC·Filed 2021·Application pending·0 cites
- 2559US2021292285A1Heterocyclic compounds as adenosine antagonistsNUVATION BIO INC·Filed 2021·Application pending·0 cites
- 2658US2023000876A1Treating cancers with a cyclin-dependent kinase inhibitorNUVATION BIO INC·Filed 2022·Application pending·0 cites
- 2757US2022259195A1Crystalline forms of a cyclin-dependent kinase inhibitorNUVATION BIO INC·Filed 2022·Application pending·0 cites
- 2856US11332473B2Substituted pyrazolo[3,4-d]pyrimidines as Wee1 inhibitorsNUVATION BIO INC·Filed 2020·Granted May 17, 2022·0 cites·60 claims
- 2956US2023174545A1Heterocyclic compounds as bet inhibitorsNUVATION BIO INC·Filed 2021·Application pending·0 cites
- 3054US11254670B21,8-naphthyridinone compounds and uses thereofNUVATION BIO INC·Filed 2020·Granted Feb 22, 2022·0 cites·37 claims
- 3153US11299493B2Heterocyclic compounds and uses thereofNUVATION BIO INC·Filed 2018·Granted Apr 12, 2022·0 cites·34 claims
- 3252US2025326756A1Method for producing 3,6-disubstituted-imidazo[1,2-b]pyridazine compoundsNUVATION BIO INC·Filed 2022·Application pending·0 cites
- 3350US2022162229A1Heterocyclic compounds and uses thereofNUVATION BIO INC·Filed 2020·Application pending·0 cites
- 3449US2022347187A1Heterocyclic compounds as kinase inhibitorsNUVATION BIO INC·Filed 2020·Application pending·0 cites
- 3549US2022273659A1Heterocyclic compounds as kinase inhibitorsNUVATION BIO INC·Filed 2020·Application pending·0 cites
- 3648US2022281859A1Heterocyclic compounds as kinase inhibitorsNUVATION BIO INC·Filed 2020·Application pending·0 cites
- 3747US2022220115A1Heterocyclic compounds and uses thereofNUVATION BIO INC·Filed 2020·Application pending·0 cites
- 3846US2022168313A1Heterocyclic compounds and uses thereofNUVATION BIO INC·Filed 2020·Application pending·0 cites
- 3945US2023066315A1Compounds and uses thereofNUVATION BIO INC·Filed 2020·Application pending·0 cites
- 4044US2022169646A1Heterocyclic compounds and uses thereofNUVATION BIO INC·Filed 2020·Application pending·0 cites
- 4143US2022119367A1Heterocyclic compounds as adenosine antagonistsNUVATION BIO INC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when NUVATION BIO INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →